Abreva and Application site erythema - a phase IV clinical study of FDA data
Application site erythema is found among people who take Abreva, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Abreva and have Application site erythema. It is created by eHealthMe based on reports of 15,949 people who have side effects when taking Abreva from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
15,949 people reported to have side effects when taking Abreva.
Among them, 274 people (1.72%) have Application site erythema.
What is Abreva?
Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 15,961 Abreva users for its effectiveness, alternative drugs and more.
What is Application site erythema?
Application site erythema (redness of the skin at application site) is found to be associated with 1,130 drugs and 850 conditions by eHealthMe.
Number of Abreva and Application site erythema reports submitted per year:
Time on Abreva when people have Application site erythema *:
Gender of people who have Application site erythema when taking Abreva*:
Age of people who have Application site erythema when taking Abreva *:
Common drugs people take besides Abreva *:
Common side effects people have besides Application site erythema *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Abreva and have Application site erythema?Check whether Application site erythema is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of Abreva:
- Abreva (15,961 reports)
Application site erythema treatments and more:
- Application site erythema (24,256 reports)
COVID vaccines that are related to Application site erythema:
- Application site erythema in Moderna COVID Vaccine
- Application site erythema in Pfizer BioNTech Covid Vaccine
- Application site erythema in Johnson and Johnson Covid Vaccine
How severe was Application site erythema and when was it recovered:
Expand to all the drugs that have ingredients of docosanol:
Common drugs associated with Application site erythema:
All the drugs that are associated with Application site erythema:
- Application site erythema (1,130 drugs)
Common conditions associated with Application site erythema:
All the conditions that are associated with Application site erythema:
- Application site erythema (850 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on docosanol (the active ingredients of Abreva) and Abreva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.